The glycaemic sixer [glycaemic hexad].
1Department of Endocrinology, Bharti Hospital, Karnal, India.
JPMA. the Journal of the Pakistan Medical Association
|October 15, 2018
Summary
The Glycaemic Sixer is a new diabetes care model focusing on six key glucose targets. Achieving these targets helps improve cardiovascular outcomes and promotes personalized, safe diabetes management.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Diseases
Background:
- Diabetes mellitus significantly increases cardiovascular risk.
- Current diabetes management often focuses on limited glycaemic parameters.
- Suboptimal glycaemic control contributes to adverse cardiovascular events.
Purpose of the Study:
- To introduce the Glycaemic Sixer, a novel framework for comprehensive diabetes care.
- To highlight the importance of targeting six specific glycaemic parameters for cardiovascular health.
- To advocate for a patient-centered approach in diabetes management.
Main Methods:
- Conceptual framework development based on existing evidence.
- Identification of six critical glycaemic parameters impacting cardiovascular outcomes.
- Discussion of therapeutic strategies for achieving optimal control of these parameters.
Main Results:
- The Glycaemic Sixer encompasses fasting glucose, post-prandial glucose, glycosylated haemoglobin, avoidance of hypoglycemia, avoidance of nocturnal hypoglycemia, and glycemic variability.
- All six parameters are independently associated with cardiovascular outcomes.
- Balancing these six parameters is crucial for effective diabetes management.
Conclusions:
- The Glycaemic Sixer provides a holistic approach to diabetes care, emphasizing both efficacy and safety.
- Individualized, patient-centered strategies are essential for optimal diabetes management.
- Evidence-based therapeutic agents should be utilized to target all six glycaemic parameters.
Related Concept Videos
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
501
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
501
Oral Hypoglycemic Agents: Glinides
560
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
560
Energy-requiring Steps of Glycolysis
171.0K
Glucose is the source of nearly all energy used by organisms. The first step of converting glucose into usable energy is called glycolysis. Glycolysis occurs in the cytosol of the cell over two phases: an energy-requiring phase and an energy-releasing phase. Over the first three steps, glucose is converted into different forms and attached to two phosphate groups donated by two ATP molecules, resulting in an unstable sugar. In the next two stages, the unstable sugar splits into two sugar...
171.0K
Hormones Regulating Blood Glucose
6.3K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
6.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
559
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
559
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K


